Deals in Depth: April 2010
Executive Summary
April's leaders included a $165mm deal that gave Allergan rights to Serenity's late-stage Ser120 for nocturia. Medtronic offered $313mm to buy cardiac device company ATS Medical. Of the nearly $1bn in IPO money, 85% came from one company - Shenzhen Hepalink Pharma. Follow-on dollars on the device side were strong, with two companies bringing over $70mm, while both biopharma and device companies together raised $568mm in private financings.
You may also be interested in...
Start-Up Scanwell Adds Another Collaboration, Targets Home COVID-19 Testing With BD
Scanwell Health, a leader in smartphone-enabled home diagnostics tests, has announced a partnership with Beckton Dickson.
Execs On The Move: Slew Of Directorships At Zimmer And 908 Devices
908 Devices, Zimmer Biomet and Ortho Clinical Diagnostics have all appointed new directors, Biolase promotes executive vice president to chief executive officer role, and more.
Start-Up Spotlight: Elypta Targets World’s First Metabolism-Based Early Cancer Diagnosis
The Swedish liquid biopsy start-up expects to be the first company to secure US FDA approval for a metabolism-based urine test for the early detection of kidney cancer in post-surgery patients.
Need a specific report? 1000+ reports available
Buy Reports